xylyx

Pathological ECM changes drive disease progression by regulating cell–matrix interactions. Human diseased ECM substrates, including fibrotic liver and lung ECMs, enable clinically-relevant, high-fidelity disease modeling predictive of human disease biology.

Related Resources

Application note: Accelerating anti-fibrotic drug development with human fibrotic liver ECM substrates
Application note: Accelerating anti-fibrotic drug development with human fibrotic lung ECM substrates
Fibrotic Human Lung Extracellular Matrix as a Disease-Specific Substrate for Models of Pulmonary Fibrosis
Poster: Fibrotic liver extracellular matrix substrates for 3D in-vitro models of human liver fibrosis
Poster: Fibrotic lung extracellular matrix substrates for 3D in-vitro models of human pulmonary fibrosis
Webinar: Transforming lung fibrosis drug discovery with the IN MATRICO® Human Lung Fibrosis platform